Human papillomavirus infection

PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

Retrieved on: 
Monday, May 17, 2021
Health sciences, Cancer, Clinical medicine, Virotherapy, Cancer immunotherapy, Human papillomavirus infection, Oncology, Therapy, Immunotherapy

This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development or other allowable expenditures.

Key Points: 
  • This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development or other allowable expenditures.
  • Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types.
  • The company\xe2\x80\x99s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.
  • Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
Cancer, Clinical medicine, Medicine, Virotherapy, Cancer immunotherapy, Immunotherapy, Human papillomavirus infection

Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotech.

Key Points: 
  • Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotech.
  • PDS Biotech has developed multiple therapies, based on combinations of Versamune\xc2\xae and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.
  • The Company\xe2\x80\x99s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.
  • Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Retrieved on: 
Thursday, May 13, 2021
Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Medicine, Papillomavirus, Cancer screening, Cervical screening, Human papillomavirus infection, Cervical cancer, Screening

"\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Key Points: 
  • "\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.
  • "HPV self-sampling makes screening accessible to women who don\'t participate in screening or have limited access to screening.
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Retrieved on: 
Wednesday, May 12, 2021
Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Medical specialties, Clinical medicine, Health

Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.

Key Points: 
  • Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.
  • A critical need remains for better treatment options for advanced HPV 16-associated cancers.
  • The purpose of the trial is to determine the safety and tolerability, recommended Phase 2 dose and pharmacology, and antitumor activity of RTX-321.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Cue Biopharma to Host Business Update Call and Webcast

Retrieved on: 
Monday, May 10, 2021
Otorhinolaryngology, XC2, Infectious causes of cancer, Head and neck cancer, Human papillomavirus infection, Health, Clinical medicine, Medical specialties

b'CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\xe2\x80\x99s body, announced today it will host a conference call and webcast to provide a business update on\xc2\xa0Monday, May 17, 2021\xc2\xa0at\xc2\xa04:30 p.m. EDT.

Key Points: 
  • b'CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\xe2\x80\x99s body, announced today it will host a conference call and webcast to provide a business update on\xc2\xa0Monday, May 17, 2021\xc2\xa0at\xc2\xa04:30 p.m. EDT.
  • Live and archived versions of the event can be accessed via the Company\xe2\x80\x99s website .\nMembers of the\xc2\xa0Cue Biopharma\xc2\xa0executive management team will provide a clinical update from the Company\xe2\x80\x99s ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, including discussing the confirmed partial response (PR) recently reported in one patient receiving CUE-101 as second-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.
  • Management will also provide an update on the Company\xe2\x80\x99s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.\n'

Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Branches of biology, Otorhinolaryngology, Infectious causes of cancer, Papillomavirus, Head and neck cancer, Clinical medicine, Human papillomavirus infection, Natural killer cell

This provides evidence that CUE-101 is an active agent with promising potential for HPV+ HNSCC patients.

Key Points: 
  • This provides evidence that CUE-101 is an active agent with promising potential for HPV+ HNSCC patients.
  • This is bolstered by the supporting pharmacodynamic data in which we have observed activation of disease-specific T cells and NK cells in the blood of our treated patients.
  • We anticipate a number of important milestones throughout this year with the potential of further data to inform CUE-101\xe2\x80\x99s clinical application.
  • Based on translational data from the trial, a maximum tolerated dose (MTD) or recommended Phase 2 dose will be determined.

Global Human Papillomavirus Infections Epidemiology and Patient Flow Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Infectious diseases, Cancer, Health, Epidemiology, Infectious causes of cancer, Papillomavirus, Carcinogenesis, Infectious diseases, Papillomaviridae, Human papillomavirus infection, Virus, Infection, Sexually transmitted infection

b'The "Global Human Papillomavirus Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Human Papillomavirus Infections Epidemiology and Patient Flow Analysis - 2021, provides Human Papillomavirus Infections epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Human Papillomavirus Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Human Papillomavirus Infections Epidemiology and Patient Flow Analysis - 2021, provides Human Papillomavirus Infections epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Human Papillomavirus Infections patients, history of the disease at the population level (Human Papillomavirus Infections prevalence, Human Papillomavirus Infections incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nHuman Papillomavirus Infections patient flow: Human Papillomavirus Infections prevalence, diagnosed, and drug-treated patients\nDemographics: Human Papillomavirus Infections patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Human Papillomavirus Infections market sizing, assessing market potential, and developing drug forecast models\nIdentify Human Papillomavirus Infections patients segments through age groups, gender, and disease sub-types\nEvaluate Human Papillomavirus Infections market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005368/en/\n'

Health Monitor Wins Top International Creative Awards

Retrieved on: 
Tuesday, May 4, 2021
Infectious causes of cancer, Papillomavirus, Articles, Carcinogenesis, Carcinogens, Human papillomavirus infection, Health, Clinical medicine, Medical specialties

b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.

Key Points: 
  • b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.
  • The company received numerous platinum and gold awards for their groundbreaking work in direct-to-patient marketing at the point of care.
  • Their award-winning digital and print educational materials have impacted millions of patients suffering from conditions such as diabetes, HPV, IBD, severe asthma, heart attack, stroke, and dermatologic conditions.
  • We hope our contentwhich is validated by leading key opinion leaders and medical associationsis making a difference in people\'s everyday lives.

The American Cancer Society Encourages Parents to Reschedule Missed Vaccine Visits for Kids

Retrieved on: 
Monday, May 3, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Vaccination, Human papillomavirus infection, HPV vaccine, Vaccine, Gardasil

Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.

Key Points: 
  • Dataindicate that the COVID-19 pandemic is having a negative effect on vaccination rates.
  • Most infections become undetectable, but some can go on to cause cancer.\nHPV vaccination works best when given between ages 9 and 12.
  • Children and young adults age 13 through 26 who have not been vaccinated, or who haven\'t gotten all their doses, should get the vaccine as soon as possible.
  • HPV vaccination helps protect boys from cancers of the throat, penis, and anus later in life.

Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Monday, April 19, 2021
Cancer, Infectious causes of cancer, Gynaecological cancer, Clinical medicine, Papillomavirus, Sexually transmitted diseases and infections, Vaccines, Human papillomavirus infection, Cervical cancer, HPV vaccine, Agenus

These clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-PD-1 antibodies.\n\xe2\x80\x9cWomen with recurrent or metastatic cervical cancer have a very poor prognosis and limited treatment options.

Key Points: 
  • These clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-PD-1 antibodies.\n\xe2\x80\x9cWomen with recurrent or metastatic cervical cancer have a very poor prognosis and limited treatment options.
  • Data suggest balstilimab may bring benefit to patients beyond what is available in this disease setting today,\xe2\x80\x9d said Jennifer Buell, PhD, President and Chief Operating Officer at Agenus.
  • Cervical cancer remains one of the leading causes of cancer death in women globally, annually killing more than 300,000 women worldwide.1 Despite advances in routine medical examinations and HPV vaccines, cervical cancer remains prevalent.
  • When left undetected, recurrent or metastatic cervical cancer often develops, for which there are limited treatment options and a low chance of survival.